Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension

NCT00441350 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1004

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: OM 40
DRUG: OM/HCTZ 40/12.5

Sponsor

Menarini Group

Collaborators

[object Object]